Infinity Pharmaceuticals, Inc. - Product Pipeline Review - 2014

Published: Feb, 2014 | Pages: 42 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Infinity Pharmaceuticals, Inc. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Infinity Pharmaceuticals, Inc. - Product Pipeline Review - 2014', provides an overview of the Infinity Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Infinity Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Infinity Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Infinity Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Infinity Pharmaceuticals, Inc.'s pipeline products

Reasons to buy

- Evaluate Infinity Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Infinity Pharmaceuticals, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Infinity Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Infinity Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Infinity Pharmaceuticals, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Infinity Pharmaceuticals, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Infinity Pharmaceuticals, Inc. Snapshot 5
Infinity Pharmaceuticals, Inc. Overview 5
Key Information 5
Key Facts 5
Infinity Pharmaceuticals, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Infinity Pharmaceuticals, Inc. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Infinity Pharmaceuticals, Inc. - Pipeline Products Glance 11
Infinity Pharmaceuticals, Inc. - Late Stage Pipeline Products 11
Phase III Products/Combination Treatment Modalities 11
Infinity Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
Phase I Products/Combination Treatment Modalities 13
Infinity Pharmaceuticals, Inc. - Early Stage Pipeline Products 14
Preclinical Products/Combination Treatment Modalities 14
Discovery Products/Combination Treatment Modalities 15
Infinity Pharmaceuticals, Inc. - Drug Profiles 16
duvelisib 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
IPI-940 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
retaspimycin hydrochloride 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
IPI-443 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Oncology Discovery Program 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Infinity Pharmaceuticals, Inc. - Pipeline Analysis 25
Infinity Pharmaceuticals, Inc. - Pipeline Products by Target 25
Infinity Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 26
Infinity Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 27
Infinity Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 28
Infinity Pharmaceuticals, Inc. - Recent Pipeline Updates 29
Infinity Pharmaceuticals, Inc. - Dormant Projects 36
Infinity Pharmaceuticals, Inc. - Discontinued Pipeline Products 37
Discontinued Pipeline Product Profiles 37
saridegib 37
Infinity Pharmaceuticals, Inc. - Company Statement 38
Infinity Pharmaceuticals, Inc. - Locations And Subsidiaries 40
Head Office 40
Other Locations & Subsidiaries 40
Appendix 41
Methodology 41
Coverage 41
Secondary Research 41
Primary Research 41
Expert Panel Validation 41
Contact Us 42
Disclaimer 42

List of Tables
Infinity Pharmaceuticals, Inc., Key Information 5
Infinity Pharmaceuticals, Inc., Key Facts 5
Infinity Pharmaceuticals, Inc. - Pipeline by Indication, 2014 8
Infinity Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2014 9
Infinity Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2014 10
Infinity Pharmaceuticals, Inc. - Phase III, 2014 11
Infinity Pharmaceuticals, Inc. - Phase II, 2014 12
Infinity Pharmaceuticals, Inc. - Phase I, 2014 13
Infinity Pharmaceuticals, Inc. - Preclinical, 2014 14
Infinity Pharmaceuticals, Inc. - Discovery, 2014 15
Infinity Pharmaceuticals, Inc. - Pipeline by Target, 2014 25
Infinity Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2014 26
Infinity Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2014 27
Infinity Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2014 28
Infinity Pharmaceuticals, Inc. - Recent Pipeline Updates, 2014 29
Infinity Pharmaceuticals, Inc. - Dormant Developmental Projects,2014 36
Infinity Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2014 37
Infinity Pharmaceuticals, Inc., Subsidiaries 40